Charles Rowland Elected to BIND Therapeutics Board of Directors

posted in: News | 0

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, announced that at BIND’s annual meeting of stockholders held today the company’s stockholders elected Mr. Charles A. Rowland, Jr., CPA, most recently the Read More…

BIND Therapeutics Presents Clinical Data Highlighting Unique Attributes of Lead Cancer Drug Candidate, BIND-014, at AACR 2014 Annual Meeting

posted in: News | 0

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins™, announced today that clinical data on its lead drug candidate, BIND-014, were presented at the American Association of Cancer Research (AACR) meeting. The Read More…

ARMO BioSciences Closes $30 Million Series B Financing

posted in: News | 0

ARMO BioSciences, Inc., a clinical-stage biotechnology company, today announced it raised $30 million in a Series B private financing led by NanoDimension. Existing investors Kleiner Perkins Caufield & Byers, OrbiMed and DAG Ventures also participated in the round. “This financing Read More…

Crocus licenses MLU™ technology to ARM

posted in: News | 0

Crocus Technology, a leading developer of magnetically enhanced semiconductor technologies for mobile security, embedded microcontrollers, harsh environment electronics and magnetic sensors, today announces it has licensed its Magnetic Logic Unit™ (MLU™) technology to ARM®. Magnetic Logic Unit™ (MLU) is a Read More…

1 5 6 7 8